Eton Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sean E. Brynjelsen
- Full Time Employees
- 31
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 21925 West Field Parkway Deer Park IL United States of America 60010-7208
- IPO Date
- Nov 13, 2018
- CIK
- 0001710340
- Website
- etonpharma.com
- Similar Companies
- Business
- Eton Pharmaceuticals, Inc. (ETON) is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases, primarily targeting pediatric patients. The company offers six commercial rare disease products: INCRELEX (mecasermin), a biologic for severe primary insulin-like growth factor 1 deficiency in pediatric patients; ALKINDI SPRINKLE, hydrocortisone granules for pediatric adrenocortical insufficiency; PKU GOLIKE, a medical formula for phenylketonuria; Carglumic Acid for hyperammonemia due to N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for hereditary tyrosinemia type 1; along with GALZIN for Wilson Disease, which it plans to relaunch in the U.S. in early 2025. Founded in 2017 and headquartered in Deer Park, Illinois, Eton operates in the United States and Europe, sourcing therapies globally through partnerships and efficiently navigating FDA approvals to bring innovative medicines to underserved small patient populations. Recent developments include the December 2024 acquisition of INCRELEX from Ipsen, bolstering its pediatric endocrinology portfolio and now available exclusively through AnovoRx specialty pharmacy with Eton Cares patient support, alongside the acquisition of GALZIN to expand its metabolic disease offerings.
Eton Pharmaceuticals Inc (ETON) Shares Fall 4.3% -- What GF Score of 70 Tells Investors
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
Eton Pharmaceuticals Q1 Earnings Call Highlights
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
Eton Pharmaceuticals Inc (ETON) Shares Fall 9.4% -- What GF Score of 73 Tells Investors
Eton Pharmaceuticals Announces CFO Succession Plan
Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?
Recent Price Trend in Eton Pharmaceuticals (ETON) is Your Friend, Here's Why
Does Eton Pharmaceuticals (ETON) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?
Eton Pharmaceuticals, Inc. (ETON) Q4 2025 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026